GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

359 papers

Showing 157-168 of total 359 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedSupporting evidence

Minimally Invasive vs Open Surgery for the Treatment of Spinal Spondylodiscitis: A Systematic Review and Meta-Analysis.

Tomé JOD; de Souza RC; Santana RV; de Oliveira WH; Motter BV; Foizer GA; César AEM; Rodrigues LMR

Jan 1, 2026International journal of spine surgery

2026PubMedSupporting evidence

Metabolic health in severe mental illness: bridging the mortality gap - a narrative review.

Ishaq K; Zavala GA; Siddiqi N

Jan 1, 2026Current opinion in psychiatry

2026PubMedSupporting evidence

A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists.

Yacawych WT; Wang Y; Zhou G; Hassan S; Bodur C; Walters E; Santinga JG; Sass F; deVaux M; Kernodle S; Wu I; Brown JM; Belmont-Rausch DM; Rupp AC; Tomlinson AJ; Lin Z; VanTongeren E; Secher A; Raun K; Pers TH; Seeley RJ; Myers MG Jr; Qiu W

Jan 1, 2026The Journal of clinical investigation

2026PubMedDirectly related

Hidden Malnutrition in the GLP-1 Era: Micronutrient Status, Protein Adequacy, and Lean Mass as Emerging Nutritional Considerations-A Narrative Review.

Sorić T; Sarić A; Ivanišin A; Lovrić M; Milić M; Matovinović M; Matek Sarić M

Jan 1, 2026Nutrients

2026PubMedDirectly related

Lifestyle Medicine as Co-Therapy During Incretin-Based Anti-Obesity Pharmacotherapy: Integrating Physical Activity, Nutrition, and Behavioral Strategies for Long-Term Success.

Mallardo M; Messina A; Monda V; La Marra M; Monda A; Allocca S; Casillo M; Di Maio G; Perrone P; Daniele A; Monda M; Messina G; Moscatelli F; Polito R

Jan 1, 2026Nutrients

2026PubMedDirectly related

Beyond Weight Loss: Thromboinflammation as a Candidate Mechanism for the Cardiovascular Benefit of GLP-1 Receptor Agonists.

Melnikov I; Borodko D; Alekseev V

Jan 1, 2026Cells

2026PubMedDirectly related

The Impact of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists on Body Composition in Individuals with Overweight and Obesity: A Systematic Review and Meta-Analysis.

Woźniak M; Tarcz Z; Pyczek G; Bogacka J; Diniejko A; Kuryłowicz A; Mamcarz A; Śliż D

Jan 1, 2026Journal of clinical medicine

2026PubMedSupporting evidence

Do glucagon-like peptide-1 receptor agonists influence cervical fusion outcomes? A systematic review and meta-analysis.

Alves MLM; da Silva Moura Costa AO; do Vale Moura Costa J; Garrido GA; Gonzalez JVP; Ferreira JSN; de Andrada Pereira B

Jan 1, 2026North American Spine Society journal

2026PubMedDirectly related

Comparative change in HbA1c and weight outcomes between obese and non-obese adults with type 2 diabetes mellitus treated with SGLT-2 inhibitors or GLP-1 receptor agonists.

Almohammed OA; Alshaya OA; Alduhayshi LA; Alshaibani ST; Alhamed MS; Alzeer MA; Alabdullah OM; Ibn Saqyan MF; Al Yami MS; Bin Sheraim N; Almohareb SN; Alfayez OM; Korayem GB

Jan 1, 2026Frontiers in endocrinology

2026PubMedDirectly related

Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study.

Brouer IC; Zani A; Olbrich H; Ludwig RJ; Thaçi D

Jan 1, 2026Frontiers in medicine

2026PubMedDirectly related

GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction.

Reitz J; Rosoff DB; Pacher P; Lohoff FW

Jan 1, 2026Biological psychiatry global open science

2026PubMedDirectly related

Computable longitudinal patient journeys from structured and unstructured EHR data.

Kim E; Foty R; Thakor AS; Skyler JS; Robinson LF; Park JD; Kraft M; Cairns CB; Seyfert-Margolis V

Jan 1, 2026Nature medicine